U.S. markets closed
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • Dow 30

    33,874.24
    -71.34 (-0.21%)
     
  • Nasdaq

    14,271.73
    +18.46 (+0.13%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    73.32
    +0.24 (+0.33%)
     
  • Gold

    1,778.20
    -5.20 (-0.29%)
     
  • Silver

    25.94
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1940
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • GBP/USD

    1.3965
    +0.0017 (+0.12%)
     
  • USD/JPY

    110.9440
    +0.3090 (+0.28%)
     
  • BTC-USD

    33,421.96
    +891.53 (+2.74%)
     
  • CMC Crypto 200

    800.68
    -9.51 (-1.17%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells.

  • Cellectis will receive up to $760 million in milestone payments from Cytovia for the first five TALEN gene-edited iPSC-derived NK products. It will also receive single-digit royalty payments on the net sales. 

  • Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds. 

  • The agreement utilizes Cellectis' gene-editing technology, TALEN, to yield NK and CAR-NK treatments with improved potency, persistence, and safety for various cancers, including solid tumors. Cytovia's CAR-NKs are expected to enter clinical trials by 2022.

  • Cellectis will develop custom TALEN, Cytovia will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates. Cytovia will have the worldwide license to its TALEN.

  • Price Action: CLLS moves 9.2% higher at $29.66 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.